|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Table 4. Change From Baseline in Selected Ophthalmologic Parameters During Double-Blind Treatment (safety population)** | | | | | | | | | | | |
|  |  |  |  | **Cariprazine Modal Daily Dose** | | | | | | |  |
| **Parameter, Unit** |  | **na** | **Placebo**  **N=304**  **Mean (SD)** | **na** | **1.5-3 mg**  **N=222 Mean (SD)** | **na** | **4.5-6 mg**  **N=310 Mean (SD)** | **na** | **9-12 mg**  **N=87**  **Mean (SD)** | **na** | **Overall**  **N=619 Mean (SD)** |
| IOP,  right eye | Baseline | 250 | 15.7 (2.9) | 162 | 16.1 (2.9) | 249 | 15.7 (2.9) | 74 | 14.9 (2.4) | 485 | 15.7 (2.9) |
| Change at endpoint | 250 | -0.5 (2.3) | 162 | -0.0 (2.1) | 249 | -0.3 (2.2) | 74 | 0.3 (2.7) | 485 | -0.1 (2.3) |
| IOP,  left eye | Baseline | 250 | 15.8 (2.8) | 162 | 16.1 (2.8) | 249 | 16.0 (2.8) | 74 | 15.2 (2.7) | 485 | 15.9 (2.8) |
| Change at endpoint | 250 | -0.4 (2.1) | 162 | -0.1 (2.0) | 249 | -0.4 (2.1) | 74 | 0.0 (2.4) | 485 | -0.2 (2.1) |
| Visual acuity,  right eye | Baseline | 248 | 0.084 (0.2) | 162 | 0.094 (0.3) | 249 | 0.080 (0.2) | 74 | 0.078 (0.2) | 485 | 0.085 (0.2) |
| Change at endpoint | 248 | -0.019 (0.2) | 162 | -0.008 (0.2) | 249 | 0.002 (0.2) | 74 | -0.024 (0.2) | 485 | -0.005 (0.2) |
| Visual acuity,  left eye | Baseline | 248 | 0.085 (0.2) | 162 | 0.110 (0.3) | 248 | 0.081 (0.2) | 74 | 0.099 (0.2) | 484 | 0.093 (0.2) |
| Change at endpoint | 248 | -0.017 (0.2) | 162 | -0.010 (0.2) | 248 | -0.004 (0.2) | 74 | -0.016 (0.1) | 484 | -0.018 (0.2) |
| Nuclear opalescence,  right eye | Baseline | 250 | 0.76 (0.8) | 162 | 0.70 (0.8) | 250 | 0.72 (0.8) | 74 | 0.87 (0.7) | 486 | 0.74 (0.8) |
| Change at endpoint | 250 | 0.03 (0.3) | 162 | -0.03 (0.4) | 250 | 0.02 (0.4) | 74 | 0.10 (0.4) | 486 | 0.02 (0.4) |
| Nuclear opalescence, left eye | Baseline | 250 | 0.76 (0.8) | 162 | 0.71 (0.8) | 251 | 0.73 (0.8) | 74 | 0.83 (0.6) | 487 | 0.74 (0.8) |
| Change at endpoint | 250 | 0.03 (0.4) | 162 | -0.03 (0.4) | 251 | 0.03 (0.4) | 74 | 0.10 (0.4) | 487 | 0.02 (0.4) |
| Nuclear color,  right eye | Baseline | 250 | 0.66 (0.7) | 162 | 0.66 (0.8) | 250 | 0.65 (0.7) | 74 | 0.75 (0.7) | 486 | 0.67 (0.7) |
| Change at endpoint | 250 | 0.03 (0.3) | 162 | -0.04 (0.4) | 250 | 0.01 (0.3) | 74 | 0.11 (0.3) | 486 | 0.03 (0.3) |
| Nuclear color,  left eye | Baseline | 250 | 0.66 (0.7) | 162 | 0.67 (0.8) | 251 | 0.64 (0.7) | 74 | 0.71 (0.6) | 487 | 0.66 (0.7) |
| Change at endpoint | 250 | 0.04 (0.3) | 162 | -0.03 (0.4) | 251 | 0.04 (0.3) | 74 | 0.09 (0.4) | 487 | 0.02 (0.4) |
| Cortical cataract,  right eye | Baseline | 250 | 0.24 (0.4) | 162 | 0.24 (0.4) | 250 | 0.27 (0.5) | 74 | 0.30 (0.5) | 486 | 0.26 (0.4) |
| Change at endpoint | 250 | 0.03 (0.3) | 162 | -0.01 (0.2) | 250 | -0.01 (0.2) | 74 | 0.04 (0.2) | 486 | 0.00 (0.2) |
| Cortical cataract,  left eye | Baseline | 250 | 0.24 (0.4) | 162 | 0.25 (0.4) | 251 | 0.27 (0.5) | 74 | 0.29 (0.5) | 487 | 0.27 (0.4) |
| Change at endpoint | 250 | 0.02 (0.3) | 162 | -0.02 (0.2) | 251 | 0.00 (0.2) | 74 | 0.03 (0.3) | 487 | -0.01 (0.2) |
| Posterior subcapsular  cataract, right eye | Baseline | 250 | 0.13 (0.1) | 162 | 0.18 (0.3) | 250 | 0.14 (0.1) | 74 | 0.12 (0.1) | 486 | 0.15 (0.2) |
| Change at endpoint | 250 | 0.00 (0.1) | 162 | -0.01 (0.1) | 250 | 0.00 (0.2) | 74 | 0.03 (0.1) | 486 | 0.00 (0.1) |
| Posterior subcapsular  cataract, left eye | Baseline | 250 | 0.15 (0.2) | 162 | 0.17 (0.3) | 251 | 0.14 (0.1) | 74 | 0.13 (0.1) | 487 | 0.15 (0.2) |
| Change at endpoint | 250 | 0.00 (0.1) | 162 | -0.01 (0.1) | 251 | 0.00 (0.2) | 74 | 0.02 (0.1) | 487 | 0.00 (0.1) |
| a n=number of patients within a specific category.  Based on studies RGH-MD-04 and RGH-MD-05, which used newer ophthalmology report forms. Only patients with baseline and endpoint values were included in analyses.  IOP, intraocular pressure. | | | | | | | | | | | |